These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18685459)

  • 21. Nonalcoholic fatty liver disease in children.
    Alisi A; Locatelli M; Nobili V
    Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):397-402. PubMed ID: 20531177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and low-carbohydrate diets.
    York LW; Puthalapattu S; Wu GY
    Annu Rev Nutr; 2009; 29():365-79. PubMed ID: 19575599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatty liver and the metabolic syndrome.
    Neuschwander-Tetri BA
    Curr Opin Gastroenterol; 2007 Mar; 23(2):193-8. PubMed ID: 17268250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic.
    Schattenberg JM; Schuppan D
    Curr Opin Lipidol; 2011 Dec; 22(6):479-88. PubMed ID: 22002020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
    Yilmaz Y; Atug O; Yonal O; Duman D; Ozdogan O; Imeryuz N; Kalayci C
    Med Sci Monit; 2009 Apr; 15(4):HY1-5. PubMed ID: 19333209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of nonalcoholic fatty liver disease: weight control.
    Bouneva I; Kirby DF
    Clin Liver Dis; 2004 Aug; 8(3):693-713, xii. PubMed ID: 15331070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diet and nonalcoholic fatty liver disease.
    Mensink RP; Plat J; Schrauwen P
    Curr Opin Lipidol; 2008 Feb; 19(1):25-9. PubMed ID: 18196983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeuric aspects of NAFLD. A literature review].
    Tapia NC; Avila FI; Leiva JG; Ramos MH; Avila JF; Uribe M
    Rev Gastroenterol Mex; 2006; 71(4):487-95. PubMed ID: 17542283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.
    Kaser S; Ebenbichler CF; Tilg H
    Int J Clin Pract; 2010 Jun; 64(7):968-83. PubMed ID: 20584230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of dietary carbohydrates and macronutrients in the pathogenesis of nonalcoholic fatty liver disease.
    Lê KA; Bortolotti M
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):477-82. PubMed ID: 18542010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease: a review.
    Poordad FF
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):661-70. PubMed ID: 16083334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease of obesity.
    Sachdev MS; Riely CA; Madan AK
    Obes Surg; 2006 Nov; 16(11):1412-9. PubMed ID: 17132404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.
    Tilg H; Moschen AR
    Hepatology; 2010 Nov; 52(5):1836-46. PubMed ID: 21038418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease: from clinical recognition to treatment.
    Sevastianos VA; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):59-79. PubMed ID: 19072371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orlistat in the treatment of NASH: a case series.
    Harrison SA; Ramrakhiani S; Brunt EM; Anbari MA; Cortese C; Bacon BR
    Am J Gastroenterol; 2003 Apr; 98(4):926-30. PubMed ID: 12738478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.